| INTRODUC TI ON
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) offer an unprecedented advantage for disease modeling, drug screening and many other in vitro or in vivo applications (Gerli, Maffioletti, Millet, & Tedesco, 2014; Wang et al., 2012; Xie et al., 2014) . Given their unique therapeutic potential, many studies have developed protocols for efficient differentiation of ESCs to different lineages in order to avoid formation of teratomas grafting undifferentiated ESCs. Thus, establishment of lineage-specific reporter ES/iPS cell lines would be essential for better understanding of the developmental stages of ES/iPS cells, efficient optimization of differentiation protocols and monitoring transplanted cell survival, migration in the transplantation studies (Luo et al., 2014; Porciuncula et al., 2016; Wu, Hunt, Xue, Ying, & Darabi, 2016; Zhang et al., 2016) .
Site-specific gene integration is an efficient approach to generate knock-in reporter cells. This strategy relies on targeted genome editing using designed nucleases and homologous recombination (HR) mediated introduction of the exogenous reporter cassette into the appropriate genomic locus (Leavitt & Hamlett, 2011) . The site-specific gene integration strategy allowed the reporter gene permanently in frame inclusion under the control of either an endogenous or exogenous promoter. This strategy may avoid the undesirable adverse effects caused by the random integration based methods.
However, the low efficiency of HR in ESCs makes it difficult for gene targeting in hESCs. Fortunately, site-specific nucleases allowed for efficient and specific genome editing. Transcription activator-like effector nucleases (TALENs) may be not only simply designed and constructed, but also have less off-targeting effect (Pu, Frescas, Zhang, & Feng, 2015; Wang et al., 2015) .
Endothelial failure resulting from cellular dysfunction or cell number reduction leads to many diseases such as cardiovascular diseases (Berezin & Kremzer, 2014; Ding, Shyu, Lin, & Li, 2007; Yiu & Tse, 2014) , renal disease (Dubin et al., 2016) , hemophilia A (Everett, Cleuren, Khoriaty, & Ginsburg, 2014; Fahs, Hille, Shi, Weiler, & Montgomery, 2014; Shahani et al., 2014) and so on. These diseases may be treated by transplantation of functional endothelial cells.
There are many studies that have used functional endothelial cells for treatment of cardiovascular diseases (Su, Leng, Han, He, & Li, 2013; Xu, Lee, Wang, & Tse, 2014; Yin et al., 2015) and hemophilia A (Follenzi et al., 2008; Matsui, 2012; Xu et al., 2009 ). In particular, hemophilia A, which is an X-linked recessive congenital bleeding disorder, has been identified as one of the most attractive candidates for gene therapy. Using genetically modified endothelial cells is an ideal treatment for hemophilia A Wu, Hu et al., 2016) . However, this treatment is hampered by the fact that human endothelial cells have a limitation of inadequate resource and poor self-renewal capacity. This restriction may be lifted by ESCs/iPSCs for their extensive self-renewal capacity and multi-lineage differentiation potentials. Developing such hES cell lines with endothelialspecific reporter genes by achieving selective reporter gene expression using an endothelial cell-specific promoter would be of great utility. Of note, the human gene Cdh5 that encodes vascular endothelial cadherin (VEcad), also known as CD144, is exclusively and constitutively expressed in endothelial cells (Yang et al., 2015) being considerate of a good candidate endothelial-specific reporter.
In the present study, we used TALENs to generate an endothelialspecific reporter hES cell line by targeting of the EGFP gene at the CD144 locus via HR. EGFP that is driven by endogenous CD144 promoter was specifically expressed in differentiated endothelial cells from the targeted ESCs without adverse effect, and efficient EC differentiation was confirmed from the reporter hESCs and hiPSCs, respectively, using the optimized method.
| MATERIAL S AND ME THODS

| Cell culture
HEK293T cells were maintained in DMEM (Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies) at 37°C humidified 5% CO 2 atmosphere. hiPSCs were purchased from 
| TALEN design and construction
Two pairs of TALEN targeting the 5′UTR-exon2 junction of CD144 were designed using ZiFiT software (http://zifit.partner.org/ZiFiT/) and assembled using REAL Assembly TALEN Kit from Joung lab (Sander et al., 2011) . TALENs cleavage efficiency at the CD144 exon2 site was tested by transfection of 0.5 μg each TALEN into HEK293T cells using Lipofectmaine 2000. Forty-eight hours after transfection, genomic DNA was extracted with phenol/chloroform.
Genomic region containing the targeting locus was PCR amplified, cloned and bacterial transformed. Thirty colonies were picked up and sequenced.
| EGFP reporter donor construction
Donor vector pCD144N-EGFP contains an EGFP-coding sequence from pEGFP-N1 (Addgene), a PGK-Neo cassette as described previously (Wu, Hunt et al., 2016; Wu, Hu et al., 2016) , and two homology
arms. An 831 bp left homology arm and a 568 bp right homology arm were PCR amplified from human genomic DNA. Then the four elements were ligated through an over-lap PCR and NheI sticky end recognition. 
| Gene targeting
| PCR screening and Southern blot analysis of gene targeting
The genomic DNA was extracted from the expanded clones on 24-well plates with phenol/chloroform. To detect the integration of CD144N-GFP donor into the CD144 exon2 site, PCR amplification of either 5′ or 3′-junction between the targeted transgene and the CD144-exon2 site was performed using La-Taq DNA polymerase (TaKaRa). Primers for the 5′ and 3′ junction were designed as follows: 5′ junction: F1, TCAGGGTTAAGACAGTTGGA, R1, GCTTGTCGGCCATGATAT, with a 1,673 bp product; 3′ junction: F2, CAACATACGAGCCGGAAGCA, R2, ATCGTCAGACCACCGCCTA, with a 1,115 bp product.
For Southern blot analysis, a 509 bp probe was synthesized and labeled using the DIG-dUTP Labeling Kit (Roche). Ten micrograms of genomic DNA was digested by KpnI restriction enzyme (New England Biolabs) overnight at 37°C. After alcohol purification, 5 μg digested products was electrophoresized on a 0.8% agarose gel and transferred to a positively charged nylon membrane (Roche Diagnostics), then hybridized with DIG-dUTP labeled probe. The probe primers used here were displayed in Table S1 . The bonded band was detected using the DIG Detection Kit (Roche). The expected fragment sizes were 7,570 bp and 4,658 bp for the targeted clones and H9 cells, respectively.
| Karyotyping
After being treated with 0.1 μg/ml colcemid (Sigma-Aldrich) for 4 hr, cells were trypsinized, pelleted, and incubated in 0.075 mol/L KCl for 10 min at 37°C. After being fixed with Carnoy fixative, metaphase chromosome spreads were prepared using air drying method. The chromosomes were G-banded with Giemsa Stain (Sigma-Aldrich) after appropriate baking at 75°C and digestion with trypsin.
| Derivation of ECs from hESCs and hiPSCs
Firstly, the differentiation of hESCs into ECs was carried out as previously described (Choi et al., 2009) . Briefly, hESCs were detached with 0.5 mmol/L EDTA and transferred onto 7 days old OP9 cells in OP9-diff medium (αMEM supplemented with 10% FBS and monothioglycerol [Sigma-Aldrich]). The medium was refreshed on every other day. On day 9, the differentiated cells were harvested and characterized by immunofluorescence assay.
Then, we simplified the differentiation method using OP9 conditioned medium. Briefly, the OP9 cells were plated on gelatin coated dishes with OP9 medium (80% αMEM, 20%FBS and 1% l-glu) for 5 days, then changed OP9-diff medium every day. Culture supernatants (OP9-diff-CM) were harvested and filtered daily. We used different cell density, when the undifferentiated hESCs seeded at 0.08 million cells, 0.15 million cells, 0.25 million cells per cm 2 on day 0, from day 1 the OP9-diff-CM medium was refreshed every day.
On day 9, the differentiated cells were harvested and characterized by immunofluorescence assay. The hiPSCs were differentiated into endothelial cells using this optimized method.
| Real-time quantitative reverse transcription PCR analysis
Total RNA was extracted using Trizol reagent (Sigma-Aldrich) and digested with RNase-free DNase (Thermo). Real-time quantitative reverse transcription PCR (qRT-PCR) was performed with HiScript II One
Step qRT-PCR SYBR Green Kit (Vazyme) according to the manufacturer's recommendations. The hypoxanthine phosphoribosyltransferse (HPRT) gene was used as a reference gene. Gene expression data were analyzed using the Bio-Rad CFX Manager Software (Bio-Rad). The primers used here were displayed in Table   S1 .
| Immunostaining
Cells were fixed with 4% paraformaldehyde for 20 min at room temperature and permeabilized in PBS plus 0.1% Triton X-100, then 
| Flow cytometry
The hESCs derived ECs were harvested using 0.25% Trypsin/EDTA.
After neutralization, cell suspensions were pelleted and washed in 
| Data analysis
Data were analyzed using the software GraphPad Prism 5.
| RE SULTS
| Construction of TALENs and activity detection
TELENs are composed by a customizable sequence-specific TALE DNA binding domain and a non-specific FokI nuclease domain.
TALENs can recognize specific DNA sequence and create dou- (Figure 3a) . We tested whether unintended mutations were produced during the gene editing process. G-banding analysis revealed no obvious abnormalities in gene-targeted cells (Figure 3b) . After gene targeting, we predicted five off-target sites using bioinformatic tools, (Fine, Cradick, Zhao, Lin, & Bao, 2014) no indels were found in the targeted clones 7 and 12. (Tables S2 and S3 and Figure 3c ). 
| EC differentiation from hESCs
Firstly, ECs were differentiated from targeted ES cells using the OP9 co-culture system. EGFP fluorescence was visible at the 8th day of differentiation (Figure 4a ). On the basis of the validation of the GFP reporter function, we differentiated the reporter ESCs to ECs using analysis showed that both CD144 and EGFP mRNAs were expressed (Figure 5b ). The endogenous CD144 promoter-driven EGFP expression was persistent and specific during in vitro EC differentiation. The EGFP expression was consistent with CD144 ( Figure 5c ).
F I G U R E 4 Endothelial cells (ECs) differentiation from human embryonic stem cells (hESCs). (a) Morphology and EGFP expression of the
Immunostaining showed that the EGFP expression was colocalized and consistent with CD31+ cells (Figure 5d ), Tie2+ cells (Figure 5e) and VWF+ cells (Figure 5f ).
Our findings confirmed that the EGFP expression can indicate EC differentiation specifically. We performed flow cytometry to detect the percentage of EGFP+ CD144+ cells and EGFP+ CD31+ cells ( Figure 5g ). Statistical analysis showed that EGFP+ CD144+ and EGFP+ CD31+ cells were both about 30% (Figure 5h ), indicating that the optimized differentiation method is feasible and efficient.
| EC differentiation from hiPSCs
Then we differentiated the hiPSCs to endothelial cells by this simplified approach. When the hiPSCs were seeded at 150,000 cells per cm 2 at day 0, the OP9-conditioned medium were added at day 1 (Figure 6a ), on the 7th day, cell morphological changed into epithelial cells (Figure 6a ). Immunostaining showed that the differentiated cells were CD31 positive and CD144 positive, (Figure 6b ) demonstrating that the optimized differentiation method is applicable in hiPSCs.
| D ISCUSS I ON
To evaluate developmental gene activations during cell differentiation and optimize differentiation methods, generation of transgenic reporter cell lines is a classical mode. The promoter-driven transgenic strategy is most commonly used to generate reporter cell line.
However, it has some obvious disadvantages such as the possibility of position effects, and risk of insertional mutagenesis. Moreover, necessary promoter sequences and regulatory elements have to be identified and used to avoid misregulation and weak expression of the reporter gene (Giudice & Trounson, 2008) . Hiroshi Hisatsune et al. reported that the CD144 promoter, when combining the 5′ flanking region and the 5′ half of the first intron of the VE-cadherin gene, can augment the activity of the 2.5-kbp 5′ promoter region while maintaining endothelial specificity (Hisatsune et al., 2005) .
Several studies have reported that construction of CDH5 reporter cell lines is done in various ways. Rafii et al. (2013) Given that the promoterless EGFP could be driven by the endogenous EC-specific promoter, in the present study we selected the CD144 locus, one of the classic markers of ECs (Lampugnani et al., 1992; Mao et al., 2013; Morton, Chaston, Baillie, Hill, & Matthaei, 2014) , as the target site for tracing endothelial differentiation.
However, like some other common endothelial markers, such as CD31 (Almendro et al., 1996) , Tie2 (Korhonen et al., 1995) , and Pselectin (Pan & McEver, 1993) , CD144 is expressed not only in endothelial cells but also in the fetal liver hematopoietic stem cells and perineurial cells of the peripheral nerve (Kim & Yilmaz Ohmorrison, 2005; Smith, Jones, & Hilton, 1998) . Therefore, we proved that EGFP was specifically expressed in endothelial cells only after coverification of several other endothelial cell markers, while indicating that our differentiation method did not significantly produce other cell types. That is to say, when the EGFP expression is highly consistent with endothelial cell markers, the EGFP expression can be applied to indicate the endothelial differentiation. In the present study we identified the ECs that are differentiated from the CDH5-GFP knock-in ES cell line by staining for EGFP and other EC differentiation markers (CD31, VWF and Tie2). At this point, using the F I G U R E 6 ECs differentiation from hiPSCs. (a) left: The OP9-conditioned medium were added at day 1, right: on the 7th day, cell morphological changeed into epithelial cells. (b) Immunostaining of hiPSCs-ECs express markers for CD31 (red), CD144 (green), DAPI was used to visualize the nucleus CDH5/CD144 expression to indicate endothelial differentiation is valuable, in spite of some technical limitations.
It has been reported that the reporter gene with the exogenous CD144 promoter was introduced into hESCs via lentivirus (Rafii et al., 2013) . However, challenges such as virus integration, immunogenicity and insertional mutagenesis, as well as a lack of regulatory elements, still remain. The development process of this reporter cell line was simplified owing to obviation of the requirement for promoter and/or enhancer elements within the exogenous donor and the resulted reporter hESCs expressed EGFP robustly and persistently during EC differentiation. To our knowledge, in situ sitespecific CD144 promoter-EGFP reporter hESC line is reported for the first time.
We optimized the differentiation method of hESCs into ECs using this hESC reporter cell line. To date, there are many studies on the EC differentiation from ESCs. A variety of methods have been used to achieve an efficient EC differentiation, including mediating embryoid body (EB) formation , the sequential usage of BIO and VEGF (Tatsumi et al., 2011) or co-culturing with mouse stromal cells (Choi et al., 2009 ). The approaches of EB mediated dif- secreted proteins play an important role during the co-culture differentiation (Figueiredo, Costa, Orellana, Picanco-Castro, & Covas, 2015) . Therefore, we modified the differentiation protocol based on the OP9 co-culture system. Differentiation of ECs from hiPSCs was succeeded by culturing hESCs in collected OP9-conditioned medium. Our results indicated that the optimal differentiation cell density was 150,000 cells per cm 2 at day 0 when ECs were derived from hESCs using OP9-conditioned medium, with an efficiency of approximately 30% on day 9. This differentiation protocol was applied to EC differentiation from hiPSCs, resulting in an efficient and simplified endothelial differentiation approach without contamination of mouse cell components.
In summary, we constructed a pair of TALENs targeting CD144
to generate an EGFP reporter hES cell line, which expressed EGFP and CD144 increasingly and specifically without unexpected effects during the EC differentiation. The EC differentiation protocol was optimized and applied to EC differentiation from hiPSCs, resulting in an efficient and simplified endothelial differentiation approach.
This is the first report of an efficient EC differentiation of hESCs and hiPSCs by generating the lineage-specific site-specific integration reporter cell lines, showing great potential to be applied in the fields such as trafficking genes and cell fate in vivo in animal models.
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